These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 8641618)
1. Proliferation index determined by MIB-1 and recurrence in endometrial cancer. Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE Gynecol Oncol; 1996 Jun; 61(3):373-7. PubMed ID: 8641618 [TBL] [Abstract][Full Text] [Related]
2. MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow-up. Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W Gynecol Oncol; 1999 Dec; 75(3):432-6. PubMed ID: 10600302 [TBL] [Abstract][Full Text] [Related]
3. The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract. Chowdhury GM; Kojima K; Kanayama H; Tsuji M; Kurokawa Y; Kagawa S Cancer; 1996 Aug; 78(4):827-33. PubMed ID: 8756378 [TBL] [Abstract][Full Text] [Related]
4. DNA index by image analysis in advanced endometrial carcinoma. Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE J Surg Oncol; 1996 Oct; 63(2):91-4. PubMed ID: 8888800 [TBL] [Abstract][Full Text] [Related]
5. Assessment of proliferation index with MIB-1 as a prognostic factor in radiation therapy for cervical cancer. Suzuki M; Tsukagoshi S; Saga Y; Ohwada M; Sato I Gynecol Oncol; 2000 Nov; 79(2):300-4. PubMed ID: 11063661 [TBL] [Abstract][Full Text] [Related]
6. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308 [TBL] [Abstract][Full Text] [Related]
7. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111 [TBL] [Abstract][Full Text] [Related]
8. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival. Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115 [TBL] [Abstract][Full Text] [Related]
9. MIB 1 immunostaining in stage I squamous cervical carcinoma: relationship with natural killer cell activity. Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de Nictolis M; Muzzioli M; Fabris N; Romanini C; Biagini G Gynecol Oncol; 1995 Jul; 58(1):28-33. PubMed ID: 7789886 [TBL] [Abstract][Full Text] [Related]
10. Markov texture parameters as prognostic indicators in endometrial cancer. Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE Gynecol Oncol; 1996 Aug; 62(2):174-80. PubMed ID: 8751546 [TBL] [Abstract][Full Text] [Related]
11. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926 [TBL] [Abstract][Full Text] [Related]
12. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer. Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811 [TBL] [Abstract][Full Text] [Related]
13. Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma. Geisler JP; Geisler HE; Wiemann MC; Zhou Z; Miller GA; Crabtree W Gynecol Oncol; 1998 Nov; 71(2):305-7. PubMed ID: 9826476 [TBL] [Abstract][Full Text] [Related]
14. The role of MIB-1 index in the prognosis of resectable pancreatic head cancer. Shyr YM; Su CH; Li AF; Wu CW; Lui WY Hepatogastroenterology; 1999; 46(29):2968-73. PubMed ID: 10576384 [TBL] [Abstract][Full Text] [Related]
15. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441 [TBL] [Abstract][Full Text] [Related]
16. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691 [TBL] [Abstract][Full Text] [Related]
17. p53 as a prognostic indicator in endometrial cancer. Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE Gynecol Oncol; 1996 May; 61(2):245-8. PubMed ID: 8626141 [TBL] [Abstract][Full Text] [Related]
18. The role of p27 in endometrial carcinoma. Nycum LR; Smith LM; Farley JH; Kost ER; Method MW; Birrer MJ Gynecol Oncol; 2001 May; 81(2):242-6. PubMed ID: 11330957 [TBL] [Abstract][Full Text] [Related]
19. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472 [TBL] [Abstract][Full Text] [Related]
20. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]